Catalyst
Slingshot members are tracking this event:
FDA Approves Merck’s (MRK) KEYTRUDA (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MRK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 19, 2019
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Keytruda, Pembrolizumab, Melanoma
